Generic Drug Entry Prior To Patent Expiration
Download Generic Drug Entry Prior To Patent Expiration full books in PDF, epub, and Kindle. Read online free Generic Drug Entry Prior To Patent Expiration ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads.
Author |
: |
Publisher |
: DIANE Publishing |
Total Pages |
: 129 |
Release |
: 2002 |
ISBN-10 |
: 9781428951938 |
ISBN-13 |
: 1428951938 |
Rating |
: 4/5 (38 Downloads) |
Synopsis Generic drug entry prior to patent expiration an FTC study by :
Author |
: |
Publisher |
: U.S. Government Printing Office |
Total Pages |
: 94 |
Release |
: 1998 |
ISBN-10 |
: PURD:32754071785707 |
ISBN-13 |
: |
Rating |
: 4/5 (07 Downloads) |
Synopsis How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry by :
Author |
: Robin Feldman |
Publisher |
: Cambridge University Press |
Total Pages |
: 165 |
Release |
: 2017-06-09 |
ISBN-10 |
: 9781316739495 |
ISBN-13 |
: 131673949X |
Rating |
: 4/5 (95 Downloads) |
Synopsis Drug Wars by : Robin Feldman
While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.
Author |
: Kenneth L. Dorsney |
Publisher |
: American Bar Association |
Total Pages |
: 0 |
Release |
: 2012 |
ISBN-10 |
: 1614384789 |
ISBN-13 |
: 9781614384786 |
Rating |
: 4/5 (89 Downloads) |
Synopsis ANDA Litigation by : Kenneth L. Dorsney
Examining the intersection between the statutory and regulatory scheme governing approval of generic pharmaceuticals and U.S. patent law in the context of Paragraph IV ANDA litigation, this comprehensive guide focuses on current and developing law as well as litigation strategies and tactics. This ready roadmap begins with an explanation of the Hatch-Waxman Act, its implementation, and litigation. Other topics include preparing and trying the case, post-trial issues and appeals, remedies, settlement, antitrust implications, and litigation of pharmaceuticals outside the U.S.
Author |
: United States. Federal Trade Commission |
Publisher |
: |
Total Pages |
: |
Release |
: 2002 |
ISBN-10 |
: OCLC:50438405 |
ISBN-13 |
: |
Rating |
: 4/5 (05 Downloads) |
Synopsis Generic Drug Entry Prior to Patent Expiration by : United States. Federal Trade Commission
In April 2001, the Commission began an industry-wide study focused on certain aspects of generic drug competition under the Hatch-Waxman Amendments. The Amendments provide certain methods by which generic drug manufacturers can obtain approval to market a generic version of a brand-name product. The study's purpose was to provide a more complete picture of how generic drug competition has developed under one method the Amendments established: generic entry prior to expiration of the brand-name company's patents on the relevant drug product.
Author |
: Michael Kremer |
Publisher |
: |
Total Pages |
: 56 |
Release |
: 1996 |
ISBN-10 |
: STANFORD:36105021000893 |
ISBN-13 |
: |
Rating |
: 4/5 (93 Downloads) |
Synopsis A Mechanism for Encouraging Innovation by : Michael Kremer
Author |
: United States. Federal Trade Commission |
Publisher |
: William s Hein & Company |
Total Pages |
: 113 |
Release |
: 2002-01-01 |
ISBN-10 |
: 1575887452 |
ISBN-13 |
: 9781575887456 |
Rating |
: 4/5 (52 Downloads) |
Synopsis Generic Drug Entry Prior to Patent Expiration by : United States. Federal Trade Commission
"In April 2001, the Commission began an industry-wide study focused on certain aspects of generic drug competition under the Hatch-Waxman Amendments. The Amendments provide certain methods by which generic drug manufacturers can obtain approval to market a generic version of a brand-name product. The study's purpose was to provide a more complete picture of how generic drug competition has developed under one method the Amendments established: generic entry prior to expiration of the brand-name company's patents on the relevant drug product. This report sets forth the results of the study. The study was prompted, in part, by the Commission's enforcement actions against alleged anticompetitive agreements that relied on certain Hatch-Waxman provisions. The study was designed to determine whether such agreements are isolated instances or more typical, and whether particular provisions of the Hatch-Waxman Amendments are susceptible to strategies to delay or deter consumer access to low-cost generic alternatives to brand-name drug products." -- from the Introduction, p. 1.
Author |
: United States. Federal Trade Commission |
Publisher |
: |
Total Pages |
: 136 |
Release |
: 2002 |
ISBN-10 |
: UCR:31210019512472 |
ISBN-13 |
: |
Rating |
: 4/5 (72 Downloads) |
Synopsis Generic Drug Entry Prior to Patient Expiration by : United States. Federal Trade Commission
Author |
: Kung-Chung Liu |
Publisher |
: Springer Nature |
Total Pages |
: 513 |
Release |
: 2019-09-06 |
ISBN-10 |
: 9789811381027 |
ISBN-13 |
: 981138102X |
Rating |
: 4/5 (27 Downloads) |
Synopsis Innovation, Economic Development, and Intellectual Property in India and China by : Kung-Chung Liu
This open access book analyses intellectual property codification and innovation governance in the development of six key industries in India and China. These industries are reflective of the innovation and economic development of the two economies, or of vital importance to them: the IT Industry; the film industry; the pharmaceutical industry; plant varieties and food security; the automobile industry; and peer production and the sharing economy. The analysis extends beyond the domain of IP law, and includes economics and policy analysis. The overarching concern that cuts through all chapters is an inquiry into why certain industries have developed in one country and not in the other, including: the role that state innovation policy and/or IP policy played in such development; the nature of the state innovation policy/IP policy; and whether such policy has been causal, facilitating, crippling, co-relational, or simply irrelevant. The book asks what India and China can learn from each other, and whether there is any possibility of synergy. The book provides a real-life understanding of how IP laws interact with innovation and economic development in the six selected economic sectors in China and India. The reader can also draw lessons from the success or failure of these sectors.
Author |
: National Academies of Sciences, Engineering, and Medicine |
Publisher |
: National Academies Press |
Total Pages |
: 235 |
Release |
: 2018-03-01 |
ISBN-10 |
: 9780309468084 |
ISBN-13 |
: 0309468086 |
Rating |
: 4/5 (84 Downloads) |
Synopsis Making Medicines Affordable by : National Academies of Sciences, Engineering, and Medicine
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.